Trofinetide
ATLPC0035847
H-Gly-aMePro-Glu-OH
- Length11 aa
- Measurements5
- Endpoints5
- Domains3/5
- Products1
- No matrix stability evidence
- 1 clearance measurement
- Product-level review pending
- No sequence liability cues
Open the matching evidence section below
Sequence & molecular identity
1 formsReviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.
Sequence & peptidoform
A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.
Identity summarySpecific molecular form represented
- Identity status
- Specific molecular form represented
- Residues
- 11
- Peptidoform features
- 5
- Documented molecular forms
- 1
- Representations
- 2
Documented molecular forms1 form linked to this peptide identity
| Form | Topology | Modifications | Connections | Representations | Measurements | |
|---|---|---|---|---|---|---|
| ATLPF0038989 | — | 4 | — | 1 | 4 |
Residue view
Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.
Features are shown only when a reported notation or topology record supports them.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported token o is not one of the 20 standard residue symbols in this display.
Reported token O is not one of the 20 standard residue symbols in this display.
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Structure & chemistry
Chemical representationsequence / HELM only
How the current release can interpret this identity chemically.
plain sequence-likeResidue string used for positional interpretation when available.
HGAMEPRXEXHPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
3D structure referencesnone attached
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
Covalent topology & modifications1 signal
| Feature | Positions | Interpretation | Link |
|---|---|---|---|
| Form-level topology | ATLPF0038989 | Open-chain form. Residue-level connection endpoints are shown separately when available. | Not linked |
Physicochemical profile
6 descriptorsComputed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.
These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.
Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.
Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.
Computed logP — distinct from the measured logD endpoint.
0 Ro5 violations · MW 315.33 Da
Exposure / Absorption
2 recordsWhat evidence describes systemic exposure or absorption?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Bioavailability1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | ~ 80 % | Eligible when experimental context matches | source-reported oral bioavailability estimate · human | Result: Approximate quantitative measurement · Molecular form: ATLPF0038989 · Route: oral · Source: Primary reference linked | Reference |
Tmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | ~ 7200-10800 seconds | Eligible when experimental context matches | human | Result: Interval measurement · Molecular form: ATLPF0038989 · Route: oral · Source: Primary reference linked | Reference |
Distribution / Barrier
2 recordsWhat is known about distribution, binding, permeability, or barrier crossing?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Vd1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | ~ 80 L | Use only explicitly reported fields | human | Result: Approximate quantitative measurement · Molecular form: ATLPF0038989 · Route: oral · Trofinetide· 12.3 Pharmacokinetics · volume of distribution single · Distribution Followi... · Source: Primary reference linked | Reference |
Plasma protein binding1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | < 6 % | Interpret as reported | human · human plasma | Result: Upper-bound measurement · Molecular form: ATLPF0038989 · Source: Primary reference linked | Reference |
Barrier and permeability assay context
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Excretion / Persistence
1 recordsWhat evidence describes clearance or persistence?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Half Life1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 30 min 1800 seconds | Interpret as reported | Half life in human plasma · human · plasma | Result: Reported point value · Molecular form: not reported · half life · T1/2· Half life in human plasma · Source: Primary reference linked | Reference |
Evidence landscape
5 recordsCross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.
A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.
Top evidence-bearing endpoint questions.
Broad context buckets, useful before comparing values.
Reference-link availability for measurement-level audit.
Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.
| # | ADMET domain | Endpoint | Reported value | Result type | Analysis use | Assay / model | Condition | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | Excretion / Persistence Persistence | Half Life | 30 min 1,800 seconds | Reported point value | Interpret as reported | Half life in human plasma · human · plasma | chembl_activity_endpoint_review_v0_1 | Reference Primary reference linked |
| 2 | Distribution / Barrier Distribution | Volume Of Distribution | ~ 80 L | Approximate quantitative measurement | Use only explicitly reported fields | human | Route: oral | Reference Primary reference linked |
| 3 | Distribution / Barrier Distribution | Plasma Protein Binding | < 6 % | Upper-bound measurement | Interpret as reported | human · human plasma | Not specified | Reference Primary reference linked |
| 4 | Exposure / Absorption Exposure | Time To Max Concentration | ~ 7,200-10,800 seconds | Interval measurement | Eligible when experimental context matches | human | Route: oral | Reference Primary reference linked |
| 5 | Exposure / Absorption Exposure | Bioavailability | ~ 80 % | Approximate quantitative measurement | Eligible when experimental context matches | source-reported oral bioavailability estimate · human | Route: oral | Reference Primary reference linked |
Product context
1 productsProduct-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.
Summary1 linked product
- Linked products
- 1
- Label context
- None
- Clinical trials
- 13
- Safety label cues
- None
Linked products1 shown
Trofinetide
Identity & reference map
5 sourcesReference-level support for checking reported names, sequence notation, and peptide identity agreement.
Summary3 reference groups
- Identity type
- identity record
- Reported notation
- 0
- Reference groups
- 3
- Measurements
- 5
- ATL peptide ID
- ATLPC0035847
Identity concordance
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.
No source-specific sequence notation has been captured in the current identity references.
H-Gly-aMePro-Glu-OH
Reference map3 reference groups
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference | DistributionExposure Plasma Protein Binding, Time To Max Concentration, Volume Of Distribution | No reported alias | 3 identity 3 evidence |
Reference | Persistence Half Life | No reported alias | 1 identity 1 evidence |
Reference | Exposure Bioavailability | No reported alias | 1 identity 1 evidence |
Data access & reproducibility
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Record scopePublic release
- ATL peptide ID
- ATLPC0035847
- Identity type
- identity record
- ADMET endpoints
- 5
- Evidence records
- 5
- Reference groups
- 3
- Release view
- Public release
Data access
Structured peptide profile
JSONPeptide-specific profile used by this page, including identity and evidence context.
Peptide catalogue
TSVComplete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.
Measurement catalogue
TSVComplete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.
Programmatic access
The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0035847' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'